Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

A mechanistic pan-cancer pathway model informed by multi-omics data interprets stochastic cell fate responses to drugs and mitogens.

Bouhaddou M, Barrette AM, Stern AD, Koch RJ, DiStefano MS, Riesel EA, Santos LC, Tan AL, Mertz AE, Birtwistle MR.

PLoS Comput Biol. 2018 Mar 26;14(3):e1005985. doi: 10.1371/journal.pcbi.1005985. eCollection 2018 Mar. Erratum in: PLoS Comput Biol. 2018 Jul 9;14(7):e1006189.

2.

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.

PMID:
16854453
3.

Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.

Ewald F, Nörz D, Grottke A, Hofmann BT, Nashan B, Jücker M.

Invest New Drugs. 2014 Dec;32(6):1144-54. doi: 10.1007/s10637-014-0149-7. Epub 2014 Aug 26.

PMID:
25152244
4.

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA.

Biochim Biophys Acta. 2007 Aug;1773(8):1263-84. Epub 2006 Oct 7. Review.

5.

PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.

Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM.

Anticancer Res. 2010 Dec;30(12):4951-8.

6.

MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.

Jiang CC, Lai F, Thorne RF, Yang F, Liu H, Hersey P, Zhang XD.

Clin Cancer Res. 2011 Feb 15;17(4):721-30. doi: 10.1158/1078-0432.CCR-10-2225. Epub 2010 Nov 18.

7.

Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.

Shingu T, Holmes L, Henry V, Wang Q, Latha K, Gururaj AE, Gibson LA, Doucette T, Lang FF, Rao G, Yuan L, Sulman EP, Farrell NP, Priebe W, Hess KR, Wang YA, Hu J, Bögler O.

J Transl Med. 2016 Feb 9;14:46. doi: 10.1186/s12967-016-0803-2.

8.

Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer.

Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW.

J Clin Endocrinol Metab. 2009 Oct;94(10):4107-12. doi: 10.1210/jc.2009-0662. Epub 2009 Sep 1.

9.

Correction: A mechanistic pan-cancer pathway model informed by multi-omics data interprets stochastic cell fate responses to drugs and mitogens.

PLOS Computational Biology Staff.

PLoS Comput Biol. 2018 Jul 9;14(7):e1006189. doi: 10.1371/journal.pcbi.1006189. eCollection 2018 Jul.

12.

Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel.

Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, Adachi K, Takahashi K, Arimoto-Ishida E, Nakatsuji Y, Tasaka K, Murata Y.

J Biol Chem. 2002 Sep 6;277(36):33490-500. Epub 2002 Jun 26.

13.

Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.

Shi H, Kong X, Ribas A, Lo RS.

Cancer Res. 2011 Aug 1;71(15):5067-74. doi: 10.1158/0008-5472.CAN-11-0140.

14.

Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.

Ricciardi MR, Scerpa MC, Bergamo P, Ciuffreda L, Petrucci MT, Chiaretti S, Tavolaro S, Mascolo MG, Abrams SL, Steelman LS, Tsao T, Marchetti A, Konopleva M, Del Bufalo D, Cognetti F, Foà R, Andreeff M, McCubrey JA, Tafuri A, Milella M.

J Mol Med (Berl). 2012 Oct;90(10):1133-44. doi: 10.1007/s00109-012-0886-z. Epub 2012 Mar 8.

PMID:
22399013
15.

Dynamic simulations of pathways downstream of ERBB-family, including mutations and treatments: concordance with experimental results.

Castagnino N, Tortolina L, Balbi A, Pesenti R, Montagna R, Ballestrero A, Soncini D, Moran E, Nencioni A, Parodi S.

Curr Cancer Drug Targets. 2010 Nov;10(7):737-57.

PMID:
20578981
16.

PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.

Asati V, Mahapatra DK, Bharti SK.

Eur J Med Chem. 2016 Feb 15;109:314-41. doi: 10.1016/j.ejmech.2016.01.012. Epub 2016 Jan 12. Review.

PMID:
26807863
17.

Integrative modeling of multi-omics data to identify cancer drivers and infer patient-specific gene activity.

Pavel AB, Sonkin D, Reddy A.

BMC Syst Biol. 2016 Feb 11;10:16. doi: 10.1186/s12918-016-0260-9.

18.

Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.

Roller DG, Axelrod M, Capaldo BJ, Jensen K, Mackey A, Weber MJ, Gioeli D.

Mol Cancer Ther. 2012 Nov;11(11):2505-15. doi: 10.1158/1535-7163.MCT-12-0461. Epub 2012 Sep 7.

19.

Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.

Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.

J Cell Physiol. 2009 Jul;220(1):214-21. doi: 10.1002/jcp.21753.

PMID:
19288493
20.

Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer.

Shin SY, Müller AK, Verma N, Lev S, Nguyen LK.

PLoS Comput Biol. 2018 Jun 19;14(6):e1006192. doi: 10.1371/journal.pcbi.1006192. eCollection 2018 Jun.

Supplemental Content

Support Center